Cargando…
Infusion of hESC derived Immunity‐and‐matrix regulatory cells improves cognitive ability in early‐stage AD mice
OBJECTIVES: In this study, we administered immunity‐and‐matrix regulatory cells (IMRCs) via tail vein (IV) and intracerebroventricular (ICV) injection to 3‐month‐old 5×FAD transgenic mice to assess the effects of IMRC transplantation on the behaviour and pathology of early‐stage Alzheimer's dis...
Autores principales: | Liu, Jing, Hou, Zongren, Wu, Jun, Liu, Kailun, Li, Da, Gao, Tingting, Liu, Wenjing, An, Bin, Sun, Yun, Mo, Fan, Wang, Liu, Wang, Yukai, Hao, Jie, Hu, Baoyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349653/ https://www.ncbi.nlm.nih.gov/pubmed/34232542 http://dx.doi.org/10.1111/cpr.13085 |
Ejemplares similares
-
First case of COVID‐19 infused with hESC derived immunity‐ and matrix‐regulatory cells
por: Wu, Jun, et al.
Publicado: (2020) -
Human ESC‐derived immunity‐ and matrix‐ regulatory cells ameliorated white matter damage and vascular cognitive impairment in rats subjected to chronic cerebral hypoperfusion
por: Zhao, Yilong, et al.
Publicado: (2022) -
Hyaluronate supports hESC‐cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction
por: Tan, Yuanqing, et al.
Publicado: (2020) -
Single-cell transcriptomics reveals the cell fate transitions of human dopaminergic progenitors derived from hESCs
por: Liang, Lingmin, et al.
Publicado: (2022) -
Phase 1 trial for treatment of COVID‐19 patients with pulmonary fibrosis using hESC‐IMRCs
por: Wu, Jun, et al.
Publicado: (2020)